Climb Bio, Inc. (CLYM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US28658R1068
Climb Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -67.88 m USD |
| EBIT | -68.17 m USD |
| Net income | -59.85 m USD |
| Diluted EPS – continuing operations | -0.88 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Climb Bio, Inc.
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
More stocks
- Tainan Spinning Co Ltd (1440.TW)
- Banca IFIS SpA (IF.MI)
- Vina Concha To (CONCHATORO.SN)
- ZheJiang ZhongKe Magnetic Co. Ltd. A (301141.SZ)
- Mistras Group, Inc. (MG)
- Crystal Growth & Energy Equipment Co. Ltd. A (688478.SS)
- HydroGraph Clean Power Inc (HG.CN)
- Alpine Banks of Colorado (ALPIB)
- SLR Investment Corp. (SLRC)
- Oma Saastopankki Oyj (OMASP.HE)
- Svolder AB (SVOL B.ST)
- Shengyuan Environmental Protection (300867.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.